Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06495164 · ClinicalTrials.gov registry record

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

A clinical trial of Breast Cancer and Malignant Neoplasm of Breast, sponsored by Pfizer.

Active
Registry status
1
Enrollment target
1
Study location

NCT06495164: Active study of Breast Cancer and Malignant Neoplasm of Breast, sponsored by Pfizer.

NCT06495164 is a study of Breast Cancer and Malignant Neoplasm of Breast that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 1 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06495164, a study of Breast Cancer and Malignant Neoplasm of Breast, is active but no longer recruiting, sponsored by Pfizer.

ACTIVE NOT RECRUITING
Registry status
1 participants
Enrollment target
1
Study location

Study Summary

Palbociclib, the first oral CDK4/6 inhibitor, is an approved medicine indicated for the treatment of a kind of advanced/metastatic breast cancer (MBC), called hormone receptors positive (HR+)/ Human epidermal growth factor receptor 2 negative (HER2-) disease. Palbociclib is given orally in combination with hormonal therapies. The purpose of this study is to better understand how Palbociclib combination is used in real-life conditions and its clinical impact compared with hormonal therapy. The study will also evaluate how long patients take the different CDK 4/6 inhibitor drugs and whether using those drugs impacts the use of chemotherapy later. Male and female patients aged 18 years old or more presenting the following conditions will be selected for the study: * HR+/HER2- MBC * First treatment with Palbociclib, hormonal therapy, or other CDK4/6 inhibitors after MBC diagnosis The study will use data without personal identity, which were obtained from medical records in routine clinical practice.

Conditions Studied

Breast Cancer Malignant Neoplasm of Breast

Interventions

  • DRUG Palbociclib
  • DRUG Abemaciclib
  • DRUG Ribociclib
  • DRUG Aromatase inhibitor

Study Locations (1)

New York

  • Pfizer New York - New York

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2024-06-24
Est. Completion 2026-12-30
Pfizer

1,845 total trials

What the registry record for NCT06495164 still lists

NCT06495164 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower).

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Palbociclib is the first listed.

NCT06495164 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06495164 about?

NCT06495164 is a clinical study titled "A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer". Palbociclib, the first oral CDK4/6 inhibitor, is an approved medicine indicated for the treatment of a kind of advanced/metastatic breast cancer (MBC), called hormone receptors positive (HR+)/ Human epidermal growth factor receptor 2 negative (HER2-) disease. Palbociclib is given orally in combinati...

What is the current status of trial NCT06495164?

This trial is currently active not recruiting. The enrollment target is 1 participants. The study started on 2024-06-24. Estimated completion is 2026-12-30.

What conditions does trial NCT06495164 study?

This clinical trial studies the following conditions: Breast Cancer, Malignant Neoplasm of Breast.

What interventions are being tested in trial NCT06495164?

The interventions under investigation include: Palbociclib (DRUG), Abemaciclib (DRUG), Ribociclib (DRUG), Aromatase inhibitor (DRUG).

Who is sponsoring clinical trial NCT06495164?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06495164 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06495164's enrollment target sits among peer trials

1 1223rd of 1224 the lowest of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06495164, the US trial registry maintained by the National Library of Medicine. NCT06495164 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.